Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URC102 in Healthy Korean Adult Males
NCT02524678Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Aug 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in gout and hyperuricemia comparing Placebo with URC102 (2 arms). Primary endpoint: Number of participants with adverse events at 2 weeks. Started Aug 2015; status: completed.
02
Drugs
epaminurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02524678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524678.